- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04238637
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Arndt Vogel, Professor
- Phone Number: 760 +49 511 5326
- Email: Vogel.Arndt@mh-hannover.de
Study Contact Backup
- Name: Doerthe Vortmeyer, Doctor
- Phone Number: 4196 +49 069 7601
- Email: vortmeyer.doerthe@ikf-khnw.de
Study Locations
-
-
-
Dresden, Germany
- Not yet recruiting
- University Hospital Dresden
-
Contact:
- Gunnar Folprecht
-
Essen, Germany
- Not yet recruiting
- University Hospital Essen
-
Contact:
- Ken Herrmann
-
Essen, Germany
- Completed
- Clinic Essen Center
-
Halle, Germany
- Recruiting
- University Hospital Halle
-
Contact:
- Petra Buechner-Steudel
-
Hannover, Germany
- Recruiting
- Hannover Medical School
-
Contact:
- Arndt Vogel
-
Jena, Germany
- Recruiting
- University Hospital Jena
-
Contact:
- Udo Lindig
-
Munich, Germany
- Not yet recruiting
- Munich Clinic Bogenhausen
-
Contact:
- Martin Fuchs
-
Munich, Germany
- Not yet recruiting
- University Hospital Munich Grosshadern
-
Contact:
- Jens Ricke
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fully-informed written consent and locally required authorization (European Union [EU]: General Data Privacy Regulation (GDPR)) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.
- Age ≥ 18 years.
Histologically documented diagnosis of locally-advanced OR limited metasized intrahepatic BTC not amenable to curative treatment (tumor resection or ablation), specified as
- Tumor being confined to the liver or
In case of presence of extrahepatic lesions, metastasis must be stable AND of limited extent* AND patient must have a potential benefit from study participation in comparison to standard of care systemic therapy per local tumor board evaluation.
*Limited extent is defined in this protocol as presence of
- EITHER ≤3 malignant extrahepatic lymph nodes (short axis diameter ≥3cm)
- OR metastatic lesions in one organ other than liver (if only single lesion is present diameter MUST be < 3cm; if up to 3 lesions in one organ each lesion MUST be ≤ 1cm).
- Presence of peritoneal or brain metastatsis excludes patients from study participation (see exclusion criterion #4)
- Tumor tissue (block or at least 4 slides) is available for translational research.
Patients with prior chemotherapy and/or immunotherapy can be enrolled if ONE of the following criteria is met:
- Capecitabin or gemcitabine+cisplatin in the adjuvant setting
- Experienced progressive disease under gemcitabine+cisplatin therapy in the advanced setting
- Stable disease after 3 months of gemcitabine+cisplatin treatment
- Experienced progressive disease under durvalumab+ gemcitabine+cisplatin in first line treatment
- Experienced progressive disease under pembrolizumab+ gemcitabine+cisplatin in first line treatment
Has been considered candidate for standard-of-care Y-90 SIRT therapy per Investigator decision and after prior consultation with the tumor board if available at site and does not display contraindications against SIRT.
Contraindications against SIRT would be
- hepatic tumor load > 50%
- any Gastrointestinal deposition that cannot be corrected via angiographic techniques
- irreversibly elevated serum bilirubin
- renal insufficiency
- increased pulmonary shunt fraction being able to deliver > 16.5 mCi to the lungs
- gastrointestinal ulceration
- hepatic dysfunction
- biliary complications
- portal hypertension
- vascular injury and lymphopenia.
- Performance status (PS) ≤ 1 (ECOG scale).
- Body weight >30 kg
- At least one measurable site of disease as defined by RECIST 1.1 criteria.
- Adequate bone marrow and renal function
- Adequate hepatic function (with stenting for any obstruction, if required)
- Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial.
- Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause.
- The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations.
- Must have a life expectancy of at least 12 weeks.
If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria:
- Patients with HBV or HCV infection should be monitored for viral levels during study participation.
- Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA < 100 IU/ml and should be managed per local treatment guidelines.
Controlled (treated) hepatitis B subjects will be allowed if they started treatment at the time point of enrollment into the study by the latest and treatment is continued during study participation and for ≥ 6 months after end of study treatment.
- HCV patients with advanced BTC are mostly not treated for their HCV infection. However, patients treated for HCV are considered suitable for inclusion if antiviral therapy has been completed ≥ 30 days prior to first administration of study drug.
Exclusion Criteria:
- Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study.
- Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment.
- Prior immunotherapy or use of other investigational agents, including prior treatment with an anti-Programmed Death receptor-1 (PD-1), anti-Programmed Death-1 ligand-1 (PD-L1), anti-PD-L2, or anti-cytotoxic T-lymphocyte associated antigen-4 (anti-CTLA-4) antibody, therapeutic cancer vaccines, apart from durvalumab and pembrolizumab as PD-L1 inhibitor in first line therapy.
- Presence of peritoneal carcinomatosis or brain metastases.
- Any unresolved toxicity NCI CTCAE Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values defined in the inclusion criteria
- Any concurrent chemotherapy, investigational product (IP), biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer related conditions (eg, hormone replacement therapy) is acceptable.
- Prior radiotherapy treatment before the first dose of any study drug.
- Major surgery (as defined by the Investigator) within 4 weeks prior to enrollment into the study; patients must have recovered from effects of any major surgery. Note: Local non-major surgery for palliative intent (e.g. surgery of isolated lesions, per-cutaneous biliary drainage or biliary stenting) is acceptable.
- Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of diverticulosis], celiac disease, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis].
- Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, , serious active, uncontrolled, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent.
- History of non-infectious pneumonitis requiring steroids, or patients with Grade ≥ 2 pneumonitis.
History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of IP and of low potential risk for recurrence
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease
- History of leptomeningeal carcinomatosis
- Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a CT/ MRI of the brain prior to study entry.
- History of active primary immunodeficiency
- History of allogenic organ transplantation.
- Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or human immunodeficiency virus (positive HIV 1/2 antibodies) or active hepatitis B/hepatitis C co-infection.
- Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab.
- Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of durvalumab.
- Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product.
- Any co-existing medical condition that in the investigator's judgement will substantially increase the risk associated with the patient's participation in the study.
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
- Receipt of live attenuated vaccine within 30 days prior to the first administration of any of the IMPs and without need to receive any live attenuated vaccines during study conduct and for up to 30 days after end of Durvalumab treatment or 90 days after end of Tremelimumab treatment respectively.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Durvalumab
|
Durvalumab IV (intravenous Infusion)
Other Names:
|
Experimental: Arm 2
Durvalumab in combination with Tremelimumab
|
Durvalumab IV (intravenous Infusion)
Other Names:
Tremelimumab IV (intravenous Infusion)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response rate (ORR) according to RECIST 1.1
Time Frame: 20 months
|
Proportion of allocated subjects with best response of complete or partial response
|
20 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety (rate of adverse events)
Time Frame: From first patient included until study closure (approx. 43 months after First Patient Included)
|
Type, incidence and severity of AEs and SAEs graded according to NCI CTCAE v5.0
|
From first patient included until study closure (approx. 43 months after First Patient Included)
|
Duration of response (DoR)
Time Frame: From first measurement of CR or PR per RECIST 1.1 until disease progression occurs (up to 43 months until Study Closure)
|
Time from that the measurement criteria are first met for CR or PR (whichever is first recorded) until the first date that the PD is objectively documented or death
|
From first measurement of CR or PR per RECIST 1.1 until disease progression occurs (up to 43 months until Study Closure)
|
Progression free survival (PFS)
Time Frame: From date of randomization until disease progression occurs (up to 43 months until Study Closure)
|
Time from the date of randomization to the date of first observed disease progression (investigator assessment according to RECIST 1.1) or death from any cause
|
From date of randomization until disease progression occurs (up to 43 months until Study Closure)
|
Overall Survival (OS)
Time Frame: Date of enrollment until date of death if applicable (up to 43 months until Study Closure)
|
time from the date of treatment allocation to the date of death.
|
Date of enrollment until date of death if applicable (up to 43 months until Study Closure)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Translational research
Time Frame: 3 months
|
Exploratory: Predictive biomarkers that with a potential effect on Objective Response Rate, Duration of Response, Progression Free Survival and Overall Survival via blood sample collection + genetic subset analysis.
The following translational research is currently planned, but may be adapted taking into account new research data: Tumors will be tested for mRNA expression of PD-1, PD-L1 and PD-L2 expression, Immune cell infiltrates (IGHM, CD3, CD8, FOXP3, CD68, CD205), Chemokines (CXCL9.
CXCL10, CXCL13) and invasion markers (MMP7, MMP9)
|
3 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Salah-Eddin Al-Batran, Professor, IKF Klinische Krebsforschung GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Digestive System Neoplasms
- Biliary Tract Diseases
- Cholangiocarcinoma
- Biliary Tract Neoplasms
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Durvalumab
- Tremelimumab
Other Study ID Numbers
- IMMUWHY
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intrahepatic Cholangiocarcinoma
-
M.D. Anderson Cancer CenterActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Metastatic Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic CholangiocarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Not yet recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic CholangiocarcinomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)WithdrawnStage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Resectable Intrahepatic Cholangiocarcinoma | Stage 0 Intrahepatic Cholangiocarcinoma AJCC v8 | Stage I Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH); CelgeneActive, not recruitingResectable Cholangiocarcinoma | Stage IB Intrahepatic Cholangiocarcinoma AJCC v8 | Stage II Intrahepatic Cholangiocarcinoma AJCC v8 | Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8United States
-
Massachusetts General HospitalTerminatedResectable Intrahepatic Cholangiocarcinoma | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityActive, not recruitingStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8 | Liver and Intrahepatic Bile Duct Carcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic CholangiocarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage III Intrahepatic Cholangiocarcinoma AJCC v8 | Gallbladder Carcinoma | Metastatic Cholangiocarcinoma | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable CholangiocarcinomaUnited States
-
NRG OncologyNational Cancer Institute (NCI)TerminatedStage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic CholangiocarcinomaUnited States, Canada
-
City of Hope Medical CenterNational Cancer Institute (NCI)WithdrawnBile Duct Adenocarcinoma | Stage III Intrahepatic Cholangiocarcinoma | Stage IVA Intrahepatic Cholangiocarcinoma | Stage IVB Intrahepatic CholangiocarcinomaUnited States
-
Shanghai Zhongshan HospitalUnknownCholangiocarcinoma, IntrahepaticChina
Clinical Trials on Durvalumab
-
AstraZenecaKappa SantéRecruiting
-
Yonsei UniversityRecruitingPotentially Resectable Stage II/IIIa NSCLCKorea, Republic of
-
MedImmune LLCCompletedStage III Non-small Cell Lung Cancer | UnresectableUnited States, Canada, Italy, Spain, France, Hong Kong, Portugal, Taiwan, Poland
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Academic Thoracic Oncology Medical Investigators...AstraZenecaCompletedNon-Small Cell Lung Cancer NSCLCUnited States
-
Yonsei UniversityCompleted
-
NSABP Foundation IncCompletedRectal CancerUnited States
-
ETOP IBCSG Partners FoundationAstraZeneca AG SwitzerlandNot yet recruiting
-
AstraZenecaActive, not recruiting
-
Institut Claudius RegaudActive, not recruiting